Vascular complications of patients with type 2 diabetes in general practice in Norway in 2014 (ROSA 4) compared with 2005 (ROSA 3)
| Complications | Valid cases, 2014/2005 (%) | 2014 (n=9464) Percentages | 2005 (n=5463) Percentages | Change from 2005 to 2014 with 95% CI‡ | ||
| Microvascular complications | Observed, with 95% CI† | Adjusted‡ | Observed | Adjusted‡ | ||
| Retinopathy§ | 60/60 | 12.3 (11.1 to 13.4) | 12.2 | 14.6 | 14.8 | −2.6 (−5.1 to −0.1) |
| Neuropathy¶ | 28/21 | 18.8 (15.8 to 21.8) | 17.8 | 33.2 | 37.4 | −19.6 (−25.5 to −13.7)** |
| Pathological monofilament†† | 26/19 | 10.6 (8.2 to 13.1) | 10.0 | 21.4 | 25.0 | −15.0 (−21.5 to −8.6)** |
| Foot ulcer | 100/100 | 2.7 (2.1 to 3.2) | 2.6 | 3.3 | 3.4 | −0.8 (−1.7 to 0.2) |
| Lower limb amputation | 100/100 | 0.6 (0.5 to 0.8) | 0.6 | 0.4 | 0.5 | +0.1 (−0.1 to 0.4) |
| Nephropathy | ||||||
| Dialysis | 100/100 | 0.2 (0.1 to 0.3) | NA | |||
| Kidney transplantation | 100/100 | 0.2 (0.1 to 0.3) | NA | |||
| CKD stage (eGFR, mL/min) | 93/NA | |||||
| 45–59 | 11.2 (10.2 to 12.1) | NA | ||||
| 30–44 | 4.4 (3.8 to 5.0) | NA | ||||
| 15–29 | 1.5 (1.2 to 1.8) | NA | ||||
| <15 | 0.2 (0.1 to 0.3) | NA | ||||
| Macrovascular complications | ||||||
| Coronary heart disease‡‡ | 100/100 | 22.0 (21.0 to 22.9) | 22.7 | 25.7 | 24.3 | −1.6 (−3.2 to 0.0) |
| Stroke§§ | 100/100 | 7.3 (6.6 to 7.9) | 7.4 | 10.2 | 10.0 | −2.6 (−3.8 to −1.3)** |
| PTA/arterial surgery | 100/100 | 2.0 (1.6 to 2.3) | NA | |||
*P≤0.01, **P≤0.001.
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, county and clustering within GP practices.
§Non-proliferative/proliferative retinopathy stated in case notes regardless of time. Macular edema excluded.
¶Pathological monofilament test or foot ulcer or lower limb amputation.
††Pathological monofilament test ≥1/8.
‡‡Coronary heart disease: myocardial infarction, angina, revascularization.
§§Stroke: ischemic attack, transient ischemic attacks excluded in 2014, included in 2005.
CKD, chronic kidney disease, eGFR, estimated glomerular filtration rate; GP, general practitioner; NA, not available; PTA, percutaneous transluminal angioplasty; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study.